 Hormonal and cytotoxic chemotherapy agents are utilized in patients with metastatic or recurrent disease not amenable to radiation therapy. Hormonal agents have been used in this disease process since it has been demonstrated to be a hormonal responsive tumor. Notably, a correlation between histologic grade and the presence or absence of hormonal receptors has been noted, with well differentiated tumors more likely to express hormone receptors than those with poor histology. Furthermore, the presence of estrogen receptors ER and progesterone receptors PR varies with tumor histology. ER has been reported to be present between 70 and 87 of endometrioid adenocarcinoma and 0 and 24 in UPSC; while, PR has ranged from 67 to 91 in endometrioid tumors and 0 and 19 in UPSC. 